LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

LiDCOrapidv2 supports improved patient outcomes at

Ashford and St Peter's Hospitals

LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, is pleased to announce that, Ashford and St Peter's Hospitals NHS Foundation Trust have incorporated LiDCOrapidv2 into their Enhanced Recovery programme for patients undergoing major bowel surgery. As a result of the programme, patients now return home almost a week earlier than they would have been able to in 2008.

In a statement on the Trust's website, Mr Jonathan Trickett, Consultant Colorectal Surgeon, explains: "There is a lot of evidence to show that patients will have a better outcome and recovery if their nutrition and fluid intake is optimised before and after their operation and they are encouraged to mobilise as early as possible. This forms part of a programme known as Enhanced Recovery."

The Enhanced Recovery programme is being adopted throughout the NHS. It is aimed at improving patient outcomes and speeding up a patient's recovery after surgery. One of the focus areas for Enhanced Recovery is management of fluids, specifically use of intra-operative fluid management technologies such as the LiDCOrapidv2 with Unity software, to help patients become mobile as soon as possible after surgery.

The LiDCOrapidv2 with Unity software satisfies UK NICE (National Institute for Health and Clinical Excellence) recommendations for both the monitoring of fluids and depth of anesthesia in high risk surgery patients. It is non-invasive therefore it can be used to monitor patient fluid levels before, during and after surgery as part of an Enhanced Recovery programme.

Mr Trickett continued: "Our anaesthetists are impressed by the LiDCO machines as they help to work out precisely how much fluid the patient needs and getting this right reduces the risk of post-operative complications, such as lung or kidney problems and ileus (the bowel not working)."

From April 2013, the NHS in England will be providing payment incentives aiming to significantly increase the numbers of surgery patients that are fluid monitored from approximately 40,000 to 80,000 patients per year.

Terry O'Brien, Chief Executive Officer of LiDCO, commented: "I am delighted that our new monitor, the LiDCOrapidv2 with Unity software, is being used at St Peter's Hospital to improve patient outcomes. This is one of the first hospital trusts in the UK to purchase our recently launched multi-parameter monitor. The non-invasive nature of the LiDCOrapidv2 technology means that patients can be monitored throughout the entire surgical pathway. More comprehensive peri-operative assessment of the fluid status of the patient is now possible, which together with advances in surgery, provides a strong foundation of care to achieve the best possible outcomes. Ashford and St Peter's Hospitals NHS Foundation Trust is clearly providing exceptional levels of care and aiming to further improve the care of surgery patients."

- Ends -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.